Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Metastatic Castrate-Resistant Prostate Cancer (POSTPONE)
NCT07226713Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in castration-resistant prostate cancer (CRPC), sponsored by Medical College of Wisconsin. Started Sep 2026; status: recruiting.
02
Drugs
pacritinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07226713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226713.